



10. (Previously presented) The method of claim 6, wherein the monoclonal antibody is a humanized monoclonal antibody.

11. (Canceled)

12. (Currently amended) A method for preventing a T cell mediated autoimmune response associated with type I diabetes comprising administering to a subject in need of such treatment a prophylactically effective amount of a gp39 antagonist which is an anti-gp39 antibody or a gp39-binding fragment thereof, which antibody or fragment comprises a hypervariable region of monoclonal antibody 24-31 (ATCC Accession Number HB 11712).

13. (Previously presented) The method of claim 12, wherein the gp39 antagonist is a gp39-binding antibody fragment.

14. (Previously presented) The method of claim 13, wherein the gp39-binding antibody fragment is a Fab or F(ab')<sub>2</sub> fragment.

15-16. (Canceled)

17. (Currently amended) The method of claim 9, wherein the chimeric monoclonal anti-gp39 antibody comprises ~~variable regions~~ a variable region of monoclonal antibody 24-31.

18. (Canceled)

19. (Currently amended) The method of claim 10, wherein the humanized monoclonal anti-gp39 antibody comprises ~~variable regions~~ a hypervariable region of monoclonal antibody 24-31.

20-21. (Canceled)